English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The trial designs were generally similar. Arimidex-Nolvadex (ARNO) 95 trial included 979 women who were randomly assigned after 2 years of tamoxifen to either 3 additional years of tamoxifen or 3 years of anastrozole. The Italian Tamoxifen Arimidex (ITA) trial included 448 women who were randomly assigned after 2 – 3 years on tamoxifen to either tamoxifen or anastrozole for 2 – 3 years. In the Austrian Breast and Colorectal Cancer Study Group (ABCSG) trial, 2579 women were randomly assigned immediately after their primary surgery to receive 5 years of tamoxifen therapy or 2 years of tamoxifen followed by 3 years of anastrozole. Only the women who were event free at the 2-year point were included in the meta-analysis. With a median follow-up of 30 months for all patients in the meta-analysis, 92 (4.6%) of 2009 patients treated with anastrozole had disease recurrence, as did 159 Latest Studies Hint at Survival Advantage With Aromatase Inhibitors in Early Breast Cancer